48,401
edits
Difference between revisions of "Polymorphous adenocarcinoma"
Jump to navigation
Jump to search
Polymorphous adenocarcinoma (view source)
Revision as of 15:08, 1 October 2019
, 15:08, 1 October 2019→IHC
(→IHC) |
|||
| Line 73: | Line 73: | ||
Others: | Others: | ||
*GFAP +ve/-ve. | *GFAP +ve/-ve. | ||
**One study suggests GFAP cleanly separates the PLGA (-ve) from [[pleomorphic adenoma]] (+ve).<ref name=pmid11174597>{{Cite journal | last1 = Curran | first1 = AE. | last2 = White | first2 = DK. | last3 = Damm | first3 = DD. | last4 = Murrah | first4 = VA. | title = Polymorphous low-grade adenocarcinoma versus pleomorphic adenoma of minor salivary glands: resolution of a diagnostic dilemma by immunohistochemical analysis with glial fibrillary acidic protein. | journal = Oral Surg Oral Med Oral Pathol Oral Radiol Endod | volume = 91 | issue = 2 | pages = 194-9 | month = Feb | year = 2001 | doi = 10.1067/moe.2001.111306 | PMID = 11174597 }}</ref> | |||
*BCL2 +ve/-ve. | *BCL2 +ve/-ve. | ||
*Generally negative for myoepithelial markers (calponin, actin) - '''useful if negative'''. | *Generally negative for myoepithelial markers (calponin, actin) - '''useful if negative'''. | ||